- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
U.S. Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
Results
11
0 new
High return on equity, past performance and sound balance sheet.
11 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
MEDP | US$337.28 | -2.5% | 8.2% | US$10.4b | US$347.92 | PE28.6x | E10.8% | n/a | ||
ACAD | US$16.87 | -2.3% | -46.3% | US$2.8b | US$25.11 | PE21.8x | E28.0% | n/a | ||
EXEL | US$33.29 | -5.0% | 39.1% | US$9.6b | US$33.06 | PE20.4x | E15.8% | n/a | ||
CPRX | US$21.27 | -0.5% | 28.3% | US$2.6b | US$32.25 | PE17.8x | E17.5% | n/a | ||
PTGX | US$41.49 | 1.0% | 86.6% | US$2.4b | US$57.50 | PE14.5x | E-36.0% | n/a | ||
ETST | US$0.11 | -8.3% | 83.3% | US$33.6m | n/a | PE14.3x | n/a | n/a | ||
OBSE.F | US$0.0001 | 0% | -99.8% | US$11.7k | n/a | PE0.001x | n/a | n/a | ||
CORT | US$51.40 | -7.2% | 56.9% | US$5.4b | US$74.90 | PE38.3x | E41.4% | n/a | ||
BSEM | US$14.44 | -16.1% | 157.9% | US$256.3m | US$32.50 | PE15.1x | E33.8% | n/a | ||
PNT | US$12.50 | 0.2% | 75.1% | US$1.3b | US$12.50 | PE13.8x | E9.2% | n/a | ||
MDXG | US$9.10 | -0.7% | 2.2% | US$1.3b | US$13.40 | PE16.8x | E-1.9% | n/a |
Page 1 of 1